357P ADJUBIL: A phase II study of durvalumab and tremelimumab with or without capecitabine in ADJUvant BILiary tract cancer: The IKF/AIO-ADJUBIL trial.
Saved in:
| Title: | 357P ADJUBIL: A phase II study of durvalumab and tremelimumab with or without capecitabine in ADJUvant BILiary tract cancer: The IKF/AIO-ADJUBIL trial. |
|---|---|
| Authors: | Goetze, T.O.1 (AUTHOR), Vogel, A.2 (AUTHOR), Gonzalez Carmona, M.A.3 (AUTHOR), Habibzade, T.4 (AUTHOR), Reinecke, J.5 (AUTHOR), Adler, M.6 (AUTHOR), Pink, D.7 (AUTHOR), Ettrich, T.J.8 (AUTHOR), Roderburg, C.9 (AUTHOR), Pession, U.10 (AUTHOR), Saborowski, A.2 (AUTHOR), Van Bömmel, F.11 (AUTHOR), Wehler, T.C.12 (AUTHOR), Koehne, C-H.13 (AUTHOR), Schaaf, M.14 (AUTHOR), Sookthai, D.14 (AUTHOR), Eickhoff, R.14 (AUTHOR), Pons, M.14 (AUTHOR), Al-Batran, S-E.1 (AUTHOR), Modest, D.P.15 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 1, Vol. 36, pS140-S140. 1p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 186164240 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 357P ADJUBIL: A phase II study of durvalumab and tremelimumab with or without capecitabine in ADJUvant BILiary tract cancer: The IKF/AIO-ADJUBIL trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Goetze%2C+T%2EO%2E%22">Goetze, T.O.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Vogel%2C+A%2E%22">Vogel, A.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gonzalez+Carmona%2C+M%2EA%2E%22">Gonzalez Carmona, M.A.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Habibzade%2C+T%2E%22">Habibzade, T.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Reinecke%2C+J%2E%22">Reinecke, J.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Adler%2C+M%2E%22">Adler, M.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Pink%2C+D%2E%22">Pink, D.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ettrich%2C+T%2EJ%2E%22">Ettrich, T.J.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Roderburg%2C+C%2E%22">Roderburg, C.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Pession%2C+U%2E%22">Pession, U.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Saborowski%2C+A%2E%22">Saborowski, A.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Van+Bömmel%2C+F%2E%22">Van Bömmel, F.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wehler%2C+T%2EC%2E%22">Wehler, T.C.</searchLink><relatesTo>12</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Koehne%2C+C-H%2E%22">Koehne, C-H.</searchLink><relatesTo>13</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Schaaf%2C+M%2E%22">Schaaf, M.</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sookthai%2C+D%2E%22">Sookthai, D.</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Eickhoff%2C+R%2E%22">Eickhoff, R.</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Pons%2C+M%2E%22">Pons, M.</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Al-Batran%2C+S-E%2E%22">Al-Batran, S-E.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Modest%2C+D%2EP%2E%22">Modest, D.P.</searchLink><relatesTo>15</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2025 Supplement 1, Vol. 36, pS140-S140. 1p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=186164240 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2025.05.372 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 1 StartPage: S140 Titles: – TitleFull: 357P ADJUBIL: A phase II study of durvalumab and tremelimumab with or without capecitabine in ADJUvant BILiary tract cancer: The IKF/AIO-ADJUBIL trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Goetze, T.O. – PersonEntity: Name: NameFull: Vogel, A. – PersonEntity: Name: NameFull: Gonzalez Carmona, M.A. – PersonEntity: Name: NameFull: Habibzade, T. – PersonEntity: Name: NameFull: Reinecke, J. – PersonEntity: Name: NameFull: Adler, M. – PersonEntity: Name: NameFull: Pink, D. – PersonEntity: Name: NameFull: Ettrich, T.J. – PersonEntity: Name: NameFull: Roderburg, C. – PersonEntity: Name: NameFull: Pession, U. – PersonEntity: Name: NameFull: Saborowski, A. – PersonEntity: Name: NameFull: Van Bömmel, F. – PersonEntity: Name: NameFull: Wehler, T.C. – PersonEntity: Name: NameFull: Koehne, C-H. – PersonEntity: Name: NameFull: Schaaf, M. – PersonEntity: Name: NameFull: Sookthai, D. – PersonEntity: Name: NameFull: Eickhoff, R. – PersonEntity: Name: NameFull: Pons, M. – PersonEntity: Name: NameFull: Al-Batran, S-E. – PersonEntity: Name: NameFull: Modest, D.P. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 07 Text: 2025 Supplement 1 Type: published Y: 2025 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 36 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
